Patient Condition
Familial dilated cardiomyopathy HFrEF, LVEF 24%, NYHA class III, carrier of TTN gene mutation. My father died of heart failure, and my brother had a similar medical history.
Treatment Timeline
| Phase | Details | Date |
|---|
| Genetic assessment and family screening | | |
| Strengthen GDMT | | |
| Monitoring and adjustment | | |
| long-term management | | |
Treatment Outcome
| before | LVEF 24%, NYHA class III, NT-proBNP 5600 pg/mL, 6-minute walk distance 250m |
|---|
| after | LVEF 44%, NYHA class II, NT-proBNP 1500 pg/mL, 6-minute walking distance of 410m |
|---|
| highlight | LVEF in patients with familial DCM was increased by 20% with GDMT quadruple regimen, establishing a family cascade screening system |
|---|